Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

10 Feb 2017

• By Deanna Kamienski, Beth Allan, Maureen Riordan, Steven Muntner, and Joseph Haas

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

Tech Transfer regular column feature image

CEO Stephen Isaacs describes Aduro Biotech Inc.'s recently signed immuno-oncology collaboration with Stanford University as an effort to join wheels to a car, "so hopefully we can go on a very nice journey together."

The agreement, announced Jan. 17, will combine Aduro's personalized live, attenuated double-deleted Listeria (LADD) immunotherapy platform with an algorithm developed by Stanford associate professor of medicine Hanlee Ji to identify...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

23 May 2025

• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.